Clinton Administration request for human drugs-related activities is $233.4 mil. in FY 1994, versus a $224.5 mil. "revised 1993" spending estimate, according to more detailed figures on the request submitted to Congress April 8 ("The Pink Sheet" April 12, p. 9). The revised 1993 figures include the effects of President Clinton's Economic Stimulus package and user fees to be collected that year. Proposed funding for biologics is $154.8 mil. in 1994, up from the $118.3 mil. revised 1993 figure.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth